SOLIGENIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
SOLIGENIX, INC. (SNGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.06% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-31
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.15%.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.66%.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.06%, a 14.71% decline from fiscal 2024.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.76%, a 9.43% increase from fiscal 2023.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.35%, a 3.55% decline from fiscal 2022.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.51%, a 299.12% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.06% 10-K · filed 2026-03-31 | |||
| 2024-12-31 | 4.76% 10-K · filed 2026-03-31 | |||
| 2023-12-31 | 4.35% 10-K · filed 2025-03-21 | |||
| 2022-12-31 | 4.51% 10-K · filed 2024-03-15 | |||
| 2022-09-30 | 3.23% 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | 3.23% 10-Q · filed 2023-08-21 | |||
| 2022-03-31 | 2.15% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 1.13% 10-K · filed 2023-03-31 | |||
| 2021-09-30 | 0.67% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 0.60% 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | 1.66% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 1.66% 10-Q · filed 2021-11-12 | |||
| 2020-03-31 | 1.66% 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |